Results 361 to 370 of about 1,679,247 (398)
Some of the next articles are maybe not open access.
Microchimerism and Systemic Sclerosis
International Archives of Allergy and Immunology, 2001Systemic sclerosis (SSc) is a connective tissue disease characterized by progressive fibrosis of the skin and internal organs. SSc is an immunologically mediated disease. A prominent immunological abnormality in SSc patients is the presence of circulating autoantibodies against a variety of nuclear proteins.
SCALETTI, CRISTINA +4 more
openaire +4 more sources
SYSTEMIC SCLEROSIS (SCLERODERMA)
Acta Clinica Belgica, 2007Systemic sclerosis is a rare and often debilitating disorder characterized by a pathological triad: increased deposition of extracellular matrix and collagen in tissues, microvascular damage and dysfunction, and immune activation as evidenced by inflammation and frequent occurrence of autoantibodies.
Roufosse, Florence +1 more
openaire +3 more sources
Genetics of systemic sclerosis
Seminars in Immunopathology, 2015Systemic sclerosis (SSc) is connective tissue disorder in which fibrosis of the skin and internal organs is the main hallmark. Despite the difficulties of studying a complex disease, significant advances have been achieved in the SSc genetics field. In this review, we will describe the firmest genetic susceptibility markers known to date.
Bossini-Castillo +4 more
openaire +3 more sources
Malnutrition in systemic sclerosis
Rheumatology, 2012SSc is a chronic multi-system disease with wide-reaching consequences. Gastrointestinal features are present in over 90% of cases and these, together with other disease manifestations, may lead to nutritional decline. This produces substantial morbidity, including reliance on enteral support and even parenteral nutrition-dependent intestinal failure ...
Harrison, Elizabeth +3 more
openaire +3 more sources
Treatment of systemic sclerosis
Current Opinion in Rheumatology, 1993Guidelines for the conduct of clinical trials in progressive systemic sclerosis have been recommended to determine drug efficacy better. To date, the results of disease-modifying drugs in scleroderma have been disappointing. The treatment of esophagitis has been revolutionized by omeprazole.
openaire +5 more sources
Systemic sclerosis and infections
Autoimmunity Reviews, 2008Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular obliteration, excessive extracellular matrix deposition and fibrosis of the connective tissues of the skin, lungs, gastrointestinal tract, heart, and kidneys. Numerous infectious agents (bacterial and viral) have been proposed as possible triggering factors (Parvovirus B19 ...
BELLANDO RANDONE, SILVIA +2 more
openaire +4 more sources
2009
Systemic sclerosis and its subtypes differ significantly from other diseases in rheumatology and clinical immunology, as the aberrant activation of the immune system does not result in an inflammation-driven destruction but in a progressive matrix synthesis, especially of the skin. Owing to the recently established networks in Germany (DNSS) as well as
openaire +3 more sources
Systemic sclerosis and its subtypes differ significantly from other diseases in rheumatology and clinical immunology, as the aberrant activation of the immune system does not result in an inflammation-driven destruction but in a progressive matrix synthesis, especially of the skin. Owing to the recently established networks in Germany (DNSS) as well as
openaire +3 more sources
Monckeberg’s sclerosis in a patient with systemic sclerosis
Rheumatology International, 2009Monckeberg’s sclerosis (MS) is one of the non-inflammatory vascular diseases characterized by calcification of the media of small and medium-sized muscular arteries, but is distinct from atherosclerosis. We present a case of MS that was incidentally detected by plain X-ray in a patient with systemic sclerosis.
Soon-Young Song +3 more
openaire +3 more sources
Autoantibodies in Systemic Sclerosis
Seminars in Arthritis and Rheumatism, 2005To describe the clinical, laboratory, and prognostic features associated with the scleroderma-specific autoantibodies.Using the Pittsburgh Scleroderma Databank, all consecutive patients seen between 1980 and 1995 who had autoantibody studies performed were studied.
openaire +4 more sources
MIG chemokine in systemic sclerosis. MIG in Systemic sclerosis.
La Clinica terapeutica, 2018Several studies have proposed in Systemic sclerosis (SSc) patients that the monokine induced by interferon (IFN)-γ(MIG)/chemokine receptor (CXCR)3 axis has a determinant role in the autoimmune process and in fibrosis. Elevated MIG levels were linked to a more severe clinical phenotype, with kidney, lung and thyroid involvement.
openaire +4 more sources